Compare BridgeBio Pharma Inc (BBIO) vs JetBlue Airways Corporation (JBLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs JetBlue Airways Corporation — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while JetBlue Airways Corporation trades at $5.34 (market cap $1.99B). The key difference: BridgeBio Pharma Inc is far larger — about 8.3× JetBlue Airways Corporation's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals.
| BBIO | JBLU | |
|---|---|---|
Market Cap | $16.46B | $1.99B |
Sector | Health | Industrials |
52-Week High | $90.17 | $6.46 |
52-Week Low | $44.81 | $4.03 |
Enterprise Value | $18.02B | $9.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
JetBlue (JBLU) trades at $5.60, down 2.78% on the day, with a neutral technical signal and mixed fundamental picture. The airline reported negative net income margins of -7.78% and has missed earnings expectations in recent quarters, though it beat in Q3 2025. Recent news highlights expansion at Fort Lauderdale airport and sector-wide pressure from fuel costs. Analyst consensus is mixed with 61% hold ratings and a $5.12 price target slightly below current levels.
The outlook remains challenging with persistent losses and high debt levels, though strategic expansions and potential fuel cost relief offer some upside. Key risks include competitive pressures, volatile fuel prices, and execution of turnaround efforts. The stock presents a speculative opportunity for investors betting on operational improvements amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →
